摘要
目的本研究旨在评估孟鲁司特钠联合沙丁胺醇治疗方案在小儿支气管哮喘中的临床效果,并评估其安全性。方法选取2023年11月至2024年11月泰安市妇幼保健院儿内科门诊收治的106例支气管哮喘患儿作为研究对象,按照随机数字表法分为对照组与联合组,每组53例。对照组采用沙丁胺醇气雾剂,联合组在对照组的基础上加用口服孟鲁司特钠咀嚼片。比较两组患儿症状改善时间、肺功能、血清炎症因子水平及药物不良反应的差异。结果联合组肺部症状缓解时长短于对照组,差异有统计学意义(P<0.05)。联合组治疗后的第1秒用力呼气量(FEV_(1))、用力肺活量(FVC)、FEV_(1)占FVC的百分比、呼气流量峰值相对于预计值的百分比高于对照组,差异有统计学意义(P<0.05)。联合组治疗后白细胞介素-6、白细胞介素-8、肿瘤坏死因子-α、白三烯E_(4)水平低于对照组,差异有统计学意义(P<0.05)。联合组不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论孟鲁司特钠联合沙丁胺醇治疗小儿支气管哮喘是一种安全、有效的治疗方法,值得在临床实践中进一步推广和应用。
Objective This study aims to evaluate the clinical efficacy of the Montelukast Sodium combined with Salbutamol treatment regimen in pediatric bronchial asthma and assess its safety.Methods A total of 106 children with bronchial asthma admitted to the Department of Pediatric Internal Medicine Outpatient of Taian Maternity And Child Health Hospital from November 2023 to November 2024 were selected as the research objects,and they were divided into the control group and the combined group according to the random number table method,with 53 cases in each group.The control group was treated with Salbutamol Aerosol,and the combined group was given oral Montelukast Sodium Chewable Tablets on the basis of the control group.The differences of symptom improvement time,lung function,serum inflammatory factor levels and adverse drug reactions between the two groups of children were compared.Results The duration of pulmonary symptom relief in the combined group was longer than that in the control group,and the difference was statistically significant(P<0.05).Forced expiratory volume in first second(FEV_(1)),forced vital capacity(FVC),the ratio of FEV_(1) to FVC,and the percentage of peak expiratory flow rate in the combined group after treatment were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of interleukin-6,interleukin-8,tumor necrosis factor-αand leukotriene E_(4) in the combined group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the combined group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Montelukast Sodium combined with Salbutamol in the treatment of pediatric bronchial asthma is a safe and effective treatment method,which is worthy of further promotion and application in clinical practice.
作者
陈霞
马聪聪
CHEN Xia;MA Congcong(Department of Pediatric Internal Medicine Outpatient,Taian Maternity And Child Health Hospital,Shandong Province,Tai'an271000,China;The Fifth Department of Pediatric Internal Medicine,Taian Maternity And Child Health Hospital,Shandong Province,Tai'an271000,China)
出处
《中国当代医药》
2025年第20期75-78,共4页
China Modern Medicine
基金
山东省泰安市社会公益类应用技术项目(2024143)。
关键词
孟鲁司特钠
沙丁胺醇
小儿支气管哮喘
临床效果
Montelukast Sodium
Salbutamol
Pediatric bronchial asthma
Clinical efficacy
